Acute Myocardial Infarction Hospital Outcomes in Patients Presenting With Congestive Heart Failure Complicating Acute Myocardial Infarction

OBJECTIVES The purpose of this study was to examine treatment and outcomes in patients admitted to the hospital with acute myocardial infarction (AMI) complicated by congestive heart failure (CHF). BACKGROUND Although cardiogenic shock complicating AMI has been studied extensively, the hospital course of patients presenting with CHF is less well established. METHODS The Second National Registry of Myocardial Infarction (NRMI-2) was analyzed to determine hospital outcomes for patients with ST-elevation AMI admitted with CHF (Killip classes II or III). RESULTS Of 190,518 patients with AMI, 36,303 (19.1%) had CHF on admission. Patients presenting with CHF were older (72.6 12.5 vs. 63.2 13.5 years), more often female (46.8% vs. 32.1%), had longer time to hospital presentation (2.80 2.6 vs. 2.50 2.4 h), and had higher prevalence of anterior/septal AMI (38.8% vs. 33.3%), diabetes (33.1% vs. 19.5%), and hypertension (54.6% vs. 46.1%) (all p 0.0005). Also, they had longer lengths of stay (8.1 7.1 vs. 6.8 5.3 days, p 0.00005) and greater risk for in-hospital death (21.4% vs. 7.2%; p 0.0005). Patients with CHF were less likely to receive aspirin (75.7% vs. 89.0%), heparin (74.6% vs. 91.1%), oral beta-blockers (27.0% vs. 41.7%), fibrinolytics (33.4% vs. 58.0%), or primary angioplasty (8.6% vs. 14.6%), and more likely to receive angiotensin-converting enzyme inhibitors (25.4% vs. 13.0%). Congestive heart failure on admission was one of the strongest predictors of in-hospital death (adjusted odds ratio 1.68; 95% confidence interval 1.62, 1.75). CONCLUSIONS Patients with AMI presenting with CHF are at higher risk for adverse in-hospital outcomes. Despite this, they are less likely to be treated with reperfusion therapy and medications with proven mortality benefit. (J Am Coll Cardiol 2002;40:1389–94) © 2002 by the American College of Cardiology Foundation

[1]  Adrián Charask,et al.  Post Infarction Cardiogenic Shock: Is It Clinically Important to Differentiate Hemodynamic Patterns? , 2013 .

[2]  J. Leor,et al.  Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. , 2001, The American journal of cardiology.

[3]  H. Pereira,et al.  Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial , 2001, The Lancet.

[4]  H. Dargie,et al.  Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial , 2001, The Lancet.

[5]  L. Grines,et al.  Predictive value of the Killip classification in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. , 2001, The American journal of cardiology.

[6]  E. Antman,et al.  Application of the TIMI risk score for ST-elevation MI in the National Registry of Myocardial Infarction 3. , 2001, JAMA.

[7]  S. Kopecky,et al.  Improved survival after acute myocardial infarction in patients with advanced killip class , 2000, Clinical cardiology.

[8]  J P Ornato,et al.  Prevalence, clinical characteristics, and mortality among patients with myocardial infarction presenting without chest pain. , 2000, JAMA.

[9]  M. Gotsman,et al.  Reduction of congestive heart failure symptoms by very early fibrinolytic therapy in acute myocardial infarction: a long-term follow-up. , 2000, American heart journal.

[10]  Salim Yusuf,et al.  Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients , 2000, The Lancet.

[11]  H. S,et al.  Early Revascularization in Acute Myocardial Infarction Complicated by Cardiogenic Shock , 2000 .

[12]  A. Ciampi,et al.  Very early assessment of risk for in-hospital death among 11,483 patients with acute myocardial infarction. GISSI investigators. , 1999, American heart journal.

[13]  M. Alam,et al.  Clinical predictors of heart failure in patients with first acute myocardial infarction. , 1999, American heart journal.

[14]  J. Gore,et al.  Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. , 1999, Journal of the American College of Cardiology.

[15]  N. Every,et al.  A comparison of the national registry of myocardial infarction 2 with the cooperative cardiovascular project. , 1999, Journal of the American College of Cardiology.

[16]  E. Bates,et al.  The enduring value of Killip classification. , 1999, American heart journal.

[17]  S. Gottlieb,et al.  Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. , 1998, The New England journal of medicine.

[18]  S. Behar,et al.  Usefulness of the Killip Classification for Early Risk Stratification of Patients With Acute Myocardial Infarction in the 1990s Compared With Those Treated in the 1980s 11See Appendix for complete list of participants and their affiliations. , 1997 .

[19]  R. Califf,et al.  Clinical characteristics and long-term outcome of patients in whom congestive heart failure develops after thrombolytic therapy for acute myocardial infarction: development of a predictive model. , 1997, American heart journal.

[20]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[21]  A. Folsom,et al.  Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. , 1996, The New England journal of medicine.

[22]  Richard V. Milani,et al.  Regional Variation Across the United States in the Management of Acute Myocardial Infarction , 1996 .

[23]  H. Krumholz,et al.  Quality of care for Medicare patients with acute myocardial infarction. A four-state pilot study from the Cooperative Cardiovascular Project. , 1995, JAMA.

[24]  S. Viskin,et al.  Treatment with beta-adrenergic blocking agents after myocardial infarction: from randomized trials to clinical practice. , 1995, Journal of the American College of Cardiology.

[25]  J Col,et al.  Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. , 1995, Circulation.

[26]  R. M. Rubison,et al.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. , 1994, Circulation.

[27]  J. Herlitz,et al.  Characteristics and prognosis of patients with acute myocardial infarction in relation to occurrence of congestive heart failure. , 1994, European heart journal.

[28]  B. McNeil,et al.  Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992. , 1994, Journal of the American College of Cardiology.

[29]  Therapy Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure , 1993, The Lancet.

[30]  E. Topol,et al.  Limitations of thrombolytic therapy for acute myocardial infarction complicated by congestive heart failure and cardiogenic shock. , 1991, Journal of the American College of Cardiology.

[31]  J. Fleiss,et al.  Relation between beta-adrenergic blocker use, various correlates of left ventricular function and the chance of developing congestive heart failure. The Multicenter Diltiazem Post-Infarction Research Group. , 1990, Journal of the American College of Cardiology.

[32]  T. A. S. Group In-hospital mortality and clinical course of 20 891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin , 1990, The Lancet.

[33]  J. Tijssen,et al.  Long-term benefit of early thrombolytic therapy in patients with acute myocardial infarction: 5 year follow-up of a trial conducted by the Interuniversity Cardiology Institute of The Netherlands. , 1989, Journal of the American College of Cardiology.

[34]  L. Bolognese,et al.  RANDOMISED TRIAL OF INTRAVENOUS STREPTOKINASE, ORAL ASPIRIN, BOTH, OR NEITHER AMONG 17 187 CASES OF SUSPECTED ACUTE MYOCARDIAL INFARCTION: ISIS-2 , 1988, The Lancet.

[35]  A. Jaffe,et al.  Prognostic significance of location and type of myocardial infarction: independent adverse outcome associated with anterior location. , 1988, Journal of the American College of Cardiology.

[36]  R. Byington,et al.  Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. , 1986, Circulation.

[37]  R. Peto,et al.  Beta blockade during and after myocardial infarction: an overview of the randomized trials. , 1985, Progress in cardiovascular diseases.

[38]  R. Califf,et al.  Prognostic significance of isolated sinus tachycardia during first three days of acute myocardial infarction. , 1984, The American journal of medicine.

[39]  A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results. , 1983, JAMA.

[40]  T. Killip,et al.  Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. , 1967, The American journal of cardiology.